がん治療における細胞老化の合成的致死性代謝標的化
Jan R Dörr1, Yong Yu, Maja Milanovic
1Charité-Universitätsmedizin Berlin, Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353 Berlin, Germany.
Nature
|August 16, 2013
まとめ
治療による老化 (TIS) は,代謝の再プログラム,グルコース使用の増加,ATP生産を含む. これらの代謝要求をターゲットにすることで,老朽化した腫瘍細胞を選択的に排除し,治療結果を改善します.
科学分野:
- 腫瘍学 腫瘍学
- 細胞生物学 細胞生物学
- メタボリズムは
背景:
- 活性化された腫瘍遺伝子と化学療法により,細胞老化を誘発し,末期の成長停止状態となる.
- 治療による老化 (TIS) は治療結果を改善しますが,老化した腫瘍細胞は除去する必要があります.
- 衰老はH3K9me3のようなヒストンの改変を含み,衰老関連分泌現象型 (SASP) と関連しています.
研究 の 目的:
- TISにおける代謝再プログラミングのメカニズムを解明する.
- TISにおける代謝の脆弱性の治療的利用を探求する.
- TIS依存の代謝変化におけるSuv39h1の役割を調査する.
主な方法:
- Eμ-mycトランスジェニックマウスリンパ腫モデルを使用しました.
- TISに適合するリンパ腫とTISに適合しないリンパ腫 (Suv39h1(-)) の比較.
- 分析されたグルコース利用,ATP生成,タンパク質毒性ストレス,エンドプラズマ網膜ストレス,展開タンパク質応答 (UPR),およびユビキチネーション.
- グルコース利用とオートファギーの抑制に対する評価感度.
- Caspase-12とcaspase-3によるアポトーシスを研究した.
- 薬理学的ターゲティング in vivo を採用した.
主要な成果:
- TISに適合するリンパ腫は,TISに適合しないリンパ腫と比較して,グルコースの利用とATPの生産が増加した.
- この代謝のシフトは,タンパク質毒性ストレス,SASP,エンドプラズマ網膜ストレス,UPR,および増加したユビキチン化に関連していました.
- TISリンパ腫は,グルコース利用またはオートファギーを阻害して選択的に除去され,アポトーシスを誘導しました.
- これらの代謝要求の薬理学的ターゲティングは,腫瘍の回帰と改善されたアウトカムにつながった.
結論:
- TISは,タンパク質毒性ストレスとSASPによって駆動されるハイパーカタボリックな性質を示しています.
- TISにおける代謝の脆弱性,特にグルコース利用とオートファギーは,治療的に利用可能である.
- 合成の致死性代謝ターゲティングは,がん治療の成果を向上させるための有望な戦略です.
さらに関連する動画
関連する概念動画
Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


